UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. Vandana Singh FDA Approves UCB's Psoriasis Drug ...
Morgan Stanley analyst Sarita Kapila assumed coverage of UCB (UCBJF) with an Equal Weight rating and EUR 200 price target The firm says the hashers are “priced for perfection.” Published first ...
In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback